BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 16466913)

  • 1. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials.
    Trumper M; Ross PJ; Cunningham D; Norman AR; Hawkins R; Seymour M; Harper P; Iveson T; Nicolson M; Hickish T
    Eur J Cancer; 2006 May; 42(7):827-34. PubMed ID: 16466913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial.
    Waters JS; Norman A; Cunningham D; Scarffe JH; Webb A; Harper P; Joffe JK; Mackean M; Mansi J; Leahy M; Hill A; Oates J; Rao S; Nicolson M; Hickish T
    Br J Cancer; 1999 Apr; 80(1-2):269-72. PubMed ID: 10390007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors predicting outcome for advanced gastroesophageal cancer in elderly patients receiving palliative chemotherapy.
    Lord SR; Hall PS; McShane P; Brown J; Seymour MT
    Clin Oncol (R Coll Radiol); 2010 Mar; 22(2):107-13. PubMed ID: 20053542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
    Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy for locally advanced carcinoma of the lower oesophagus and oesophago-gastric junction.
    Forshaw MJ; Gossage JA; Chrystal K; Cheong K; Atkinson S; Botha A; Harper PG; Mason RC
    Eur J Surg Oncol; 2006 Dec; 32(10):1114-8. PubMed ID: 16621430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer.
    Tebbutt NC; Norman A; Cunningham D; Iveson T; Seymour M; Hickish T; Harper P; Maisey N; Mochlinski K; Prior Y; Hill M
    Ann Oncol; 2002 Oct; 13(10):1568-75. PubMed ID: 12377644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group Study 9601.
    Findlay M; Storey D; Gebski V; Hargreaves C; Cullingford G; Boyer M; Trotter J; Archer S; Davidson A; Johnston P; Yuen J; Dhillon H; Della-Fiorentina S; Richardson G; Truskett P; Goldstein D;
    ANZ J Surg; 2007 Apr; 77(4):247-52. PubMed ID: 17388828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma.
    Sencan O; Buyukcelik A; Yalcin B; Boruban MC; Akbulut H; Demirkazik A; Senler FC; Onur H; Icli F
    Eur J Cancer Care (Engl); 2008 Jan; 17(1):26-32. PubMed ID: 18181888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recent advances in chemotherapy for advanced gastric cancer: from the standpoint of survival advantages].
    Ohtsu A; Yoshida S; Miyata Y; Shimada Y
    Gan To Kagaku Ryoho; 1995 Mar; 22(4):444-50. PubMed ID: 7887636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis.
    Seo HY; Kim DS; Choi YS; Sung HJ; Park KH; Choi IK; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):433-9. PubMed ID: 18398608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus.
    Kulke MH; Wu B; Clark JW; Enzinger PC; Lynch TJ; Vincitore M; Michelini A; Fuchs CS
    Cancer Invest; 2006; 24(3):229-34. PubMed ID: 16809148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.
    Chau I; Norman AR; Cunningham D; Waters JS; Oates J; Ross PJ
    J Clin Oncol; 2004 Jun; 22(12):2395-403. PubMed ID: 15197201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
    Cascinu S; Labianca R; Barone C; Santoro A; Carnaghi C; Cassano A; Beretta GD; Catalano V; Bertetto O; Barni S; Frontini L; Aitini E; Rota S; Torri V; Floriani I; ; Pozzo C; Rimassa L; Mosconi S; Giordani P; Ardizzoia A; Foa P; Rabbi C; Chiara S; Gasparini G; Nardi M; Mansutti M; Arnoldi E; Piazza E; Cortesi E; Pucci F; Silva RR; Sobrero A; Ravaioli A
    J Natl Cancer Inst; 2007 Apr; 99(8):601-7. PubMed ID: 17440161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cancer chemotherapy in patients of advanced age (over 75)].
    Sasaki T; Maeda Y; Sato A; Kurihara M
    Gan To Kagaku Ryoho; 1998 Jun; 25(7):973-9. PubMed ID: 9644309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of combination chemotherapy with mitomycin and vinorelbine for the treatment of advanced non-small cell lung cancer.
    Wibmer T; Kropf C; Merk T; Schumann C; Hombach V; Krüger S
    Lung Cancer; 2008 May; 60(2):231-9. PubMed ID: 18006111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.
    Luo HY; Xu RH; Zhang L; Li YH; Shi YX; Lin TY; Han B; Wang F; Qiu MZ; He YJ; Guan ZZ
    Chemotherapy; 2008; 54(3):228-35. PubMed ID: 18560231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
    Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
    Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
    Pentheroudakis G; Fountzilas G; Kalofonos HP; Golfinopoulos V; Aravantinos G; Bafaloukos D; Papakostas P; Pectasides D; Christodoulou C; Syrigos K; Economopoulos T; Pavlidis N;
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):237-47. PubMed ID: 18243010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-fluorouracil, mitomycin-C, and polysaccharide-K adjuvant chemoimmunotherapy for locally advanced gastric cancer: the prognostic significance of frequent perineural invasion.
    Choi JH; Kim YB; Lim HY; Park JS; Kim HC; Cho YK; Han SW; Kim MW; Joo HJ
    Hepatogastroenterology; 2007; 54(73):290-7. PubMed ID: 17419278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity and tolerability of a combined palliative chemotherapy with mitomycin C, folinate, and 5-Fluorouracil in patients with advanced breast cancer after intensive pretreatment: a retrospective analysis.
    Eichbaum MH; Gast AS; Schneeweiss A; Bruckner T; Sohn C
    Am J Clin Oncol; 2007 Apr; 30(2):139-45. PubMed ID: 17414462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.